Beacon Medical Interchange

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Beacon Medical Interchange

beaconmedic.com

Lung
Testicular
Prostate
Renal Cell
Bladder
Gastrointestinal
General

Playback speed

10 seconds

Durvalumab (Imfinzi) FDA Approved for Stage III NSCLC: Standard of Care?

By Beacon Medical Interchange FEATURING Jack West

0 views

November 2, 2018

Dr. Jack West reviews key results of the PACIFIC trial of the immunotherapy agent durvalumab ...
read more ↘ (Imfinzi) vs. placebo in stage III NSCLC and explains the pros and cons of durvalumab as a new standard of care after concurrent chemoradiation.
↖ read less

Comments 0